Xingqi Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 599 million yuan, an increase of 105.98%
I'm LongbridgeAI, I can summarize articles.Xingqi Pharmaceutical released its Q3 2025 report, with operating revenue for the first three quarters reaching 1.904 billion yuan, a year-on-year increase of 32.27%; net profit attributable to shareholders was 599 million yuan, a year-on-year increase of 105.98%; net profit excluding non-recurring gains and losses was 596 million yuan, a year-on-year increase of 105.76%; basic earnings per share were 2.44 yuan
According to the Zhitong Finance APP, Xingqi Pharmaceutical (300573.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.904 billion yuan, a year-on-year increase of 32.27%. The net profit attributable to shareholders of the listed company was 599 million yuan, a year-on-year increase of 105.98%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 596 million yuan, a year-on-year increase of 105.76%. The basic earnings per share were 2.44 yuan